Ocular Therapeutix Stock Options
| OCUL Stock | USD 9.77 0.12 1.21% |
Ocular Therapeutix's latest option contracts expiring on 2024-12-20 are carrying combined implied volatility of 1.62 with a put-to-call open interest ratio of 1.2 over 10 outstanding agreements suggesting investors are buying more puts than calls on contracts expiring on 2024-12-20. The total put volume is at 15.0, with calls trading at the volume of 15.0. This yields a 0.41 put-to-call volume ratio.
Open Interest Against 2024-12-20 Option Contracts
2024-12-20
The chart above shows Ocular Therapeutix's distribution of open interest by maturity on contracts that have not yet been settled. The area between the two highest points is the projection of the price at expiration. Ocular Therapeutix's open interest chart also provides vital information regarding the liquidity of an option. If there is no open interest for Ocular Therapeutix's option, there is no secondary market available for investors to trade.
Ocular Therapeutix's option chain provides insight into all available option contracts written on Ocular Therapeutix's stock. Investors can see outstanding put and call contracts with pricing information and greeks for a given expiration period. In addition, each of Ocular Therapeutix's stock options below provides a detailed picture of the payoff. Comparing vital and dynamic information of various option contracts across diverse expiration periods will help you make an educated decision on your market timing strategies around investing in a given Ocular option contract.
In The Money vs. Out of Money Option Contracts on Ocular Therapeutix
Analyzing Ocular Therapeutix's in-the-money options over time can help investors to take a profitable long position in Ocular Therapeutix regardless of its overall volatility. This is especially true when Ocular Therapeutix's options are deep in the money. These options can be identified using deltas that are over 0.75. Deep in-the-money Ocular Therapeutix's options could be used as guardians of the underlying stock as they move almost dollar for dollar with Ocular Therapeutix's stock while costing only a fraction of its price.
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Ocular Therapeutix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.
Ocular Therapeutix In The Money Call Balance
When Ocular Therapeutix's strike price is surpassing the current stock price, the option contract against Ocular Therapeutix stock is said to be in the money. When it comes to buying Ocular Therapeutix's options that are 'In the Money' or 'Out of the Money', the choice depends on your outlook for the underlying security, financial situation, and what you are trying to achieve.
While 'out-of-the-money' option contracts written on Ocular Therapeutix are typically viewed as the more aggressive, there are potential upsides to purchasing these types of options contracts. For one, the cost to buy an 'Out of the Money' option is lower than the cost to buy an 'In the Money' option. This cost-benefit is due to the fact that at the time of the purchase, 'Out of the Money' contracts have no intrinsic value. So, while the potential for a 100% loss is more significant, the cost and risk to enter the trade are lower.
Ocular Current Options Market Mood
Ocular Therapeutix's open interest and total value indicators provide investors with the necessary information to digest the overall options buildup for its expiring contracts. In addition, it helps Ocular Stock's traders understand whether a recent fall or rise in the market is unreasonable and if the time has come to take contrarian positions. These ratios are calculated based on options trading volumes and current open interest.
Put-to-Call Open Interest
Put-to-Call Volume
Unfortunately, most Ocular Therapeutix's options investors are not very successful. Ocular Therapeutix's option open interest and volume spread between outstanding puts and calls are regarded by many investors as reliable indicators of the overall future market direction.
Rule 16 of the current Ocular contract
Base on the Rule 16, the options market is currently suggesting that Ocular Therapeutix will have an average daily up or down price movement of about 0.1% per day over the life of the 2024-12-20 option contract. With Ocular Therapeutix trading at USD 9.77, that is roughly USD 0.009892. If you think that the market is fully incorporating Ocular Therapeutix's daily price movement you should consider buying Ocular Therapeutix options at the current volatility level of 1.62%. But if you have an opposite viewpoint you should avoid it and even consider selling them.
Ocular |
Purchasing Ocular Therapeutix options can give investors a meaningful hedge against losses and, therefore, could be used conservatively to decrease the volatility of your portfolio. However, many options could also amount to little more than gambling, significantly enhancing your overall portfolio risk. One simple example of these aggressive strategies is the sale of "uncovered" Ocular calls. Remember, the seller must deliver Ocular Therapeutix stock to the call owner when a call is exercised.
Ocular Therapeutix Option Chain
When Ocular Therapeutix's strike price is surpassing the current stock price, the option contract against Ocular Therapeutix stock is said to be in the money. When it comes to buying options that are ITM or OTM, the choice depends on your outlook for the underlying security, financial situation, and what you are trying to achieve.
Ocular Therapeutix's option chain is a display of a range of information that helps investors for ways to trade options on Ocular. In general, an option chain provides a helpful tool for investors to see all available option contracts, both puts, and calls, for Ocular. It also shows strike prices and maturity days for a Ocular Therapeutix against a given expiration period. The table below combines all the option information in the form of a chain but before you use it, remember that it entails significant risk and it is not for everyone. | Open Int | Expiration | Current Spread | Last Price | |||
Call | OCUL Option Call 20-12-2024 2 | 0 | 2024-12-20 | 5.5 - 8.4 | 8.8 | In |
Call | OCUL Option Call 20-12-2024 5 | 51 | 2024-12-20 | 1.95 - 6.0 | 3.98 | In |
Call | OCUL Option Call 20-12-2024 7 | 0 | 2024-12-20 | 0.0 - 0.0 | 1.25 | In |
Call | OCUL Option Call 20-12-2024 10 | 0 | 2024-12-20 | 0.0 - 0.0 | 0.65 | |
Call | OCUL Option Call 20-12-2024 12 | 0 | 2024-12-20 | 0.0 - 0.0 | 0.05 | |
Call | OCUL Option Call 20-12-2024 15 | 0 | 2024-12-20 | 0.0 - 0.0 | 0.35 | |
Put | OCUL Option Put 20-12-2024 5 | 61 | 2024-12-20 | 0.0 - 0.25 | 0.25 | Out |
Put | OCUL Option Put 20-12-2024 7 | 0 | 2024-12-20 | 0.0 - 0.0 | 0.05 | |
Put | OCUL Option Put 20-12-2024 10 | 0 | 2024-12-20 | 0.0 - 0.0 | 0.9 | In |
Put | OCUL Option Put 20-12-2024 12 | 0 | 2024-12-20 | 0.0 - 0.0 | 2.6 | In |
Ocular Therapeutix Selling And Marketing Expenses Over Time
Selling And Marketing Expenses |
| Timeline |
Ocular Therapeutix Market Cap Over Time
Market Cap |
| Timeline |
Ocular Total Stockholder Equity
Total Stockholder Equity |
|
Ocular Therapeutix Corporate Management
| William Slattery | Vice Relations | Profile | |
| Todd Anderman | Chief Secretary | Profile | |
| William II | Vice Marketing | Profile | |
| Peter MD | Chief Officer | Profile | |
| Donald Notman | Chief Officer | Profile | |
| Philip Esq | General Counsel | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Ocular Therapeutix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. For more information on how to buy Ocular Stock please use our How to buy in Ocular Stock guide.You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ocular Therapeutix. If investors know Ocular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ocular Therapeutix listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.29) | Revenue Per Share 0.529 | Quarterly Revenue Growth 0.083 | Return On Assets (0.22) | Return On Equity (0.73) |
The market value of Ocular Therapeutix is measured differently than its book value, which is the value of Ocular that is recorded on the company's balance sheet. Investors also form their own opinion of Ocular Therapeutix's value that differs from its market value or its book value, called intrinsic value, which is Ocular Therapeutix's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ocular Therapeutix's market value can be influenced by many factors that don't directly affect Ocular Therapeutix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ocular Therapeutix's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ocular Therapeutix is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ocular Therapeutix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.